Healios K.K Management
Management criteria checks 2/4
Healios K.K's CEO is Hardy Kagimoto, appointed in Feb 2012, has a tenure of 12.83 years. directly owns 31.88% of the company’s shares, worth €29.88M. The average tenure of the management team and the board of directors is 8.8 years and 6.9 years respectively.
Key information
Hardy Kagimoto
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 12.8yrs |
| CEO ownership | 31.9% |
| Management average tenure | 8.8yrs |
| Board average tenure | 6.9yrs |
Recent management updates
Recent updates
CEO
Hardy Kagimoto (48 yo)
12.8yrs
Tenure
Dr. Tadahisa S. Kagimoto, also known as Hardy, MD, serves as Chairman, Chief Executive Officer and President of Aqumen Biopharmaceuticals, K.K. He served as Director of Athersys, Inc. since June 18, 2018 u...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 12.8yrs | no data | 31.88% € 29.9m | |
| CFO, Executive Officer & Internal Director | 5.4yrs | no data | 0.21% € 195.0k | |
| Executive Officer | no data | no data | no data | |
| Executive VP & Chief Medical Officer | 9.8yrs | no data | no data | |
| Managing Director | 8.8yrs | no data | no data | |
| Head of the Research Division | 6.3yrs | no data | no data |
8.8yrs
Average Tenure
48yo
Average Age
Experienced Management: 6VX's management team is seasoned and experienced (8.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 12.8yrs | no data | 31.88% € 29.9m | |
| CFO, Executive Officer & Internal Director | 6.9yrs | no data | 0.21% € 195.0k | |
| Independent Outside Director | 2.9yrs | no data | no data | |
| Independent External Director | 6.9yrs | no data | 0.00022% € 206.3 | |
| Auditor | 7.9yrs | no data | 0.56% € 524.3k | |
| Independent Outside Director | 2.9yrs | no data | no data |
6.9yrs
Average Tenure
66.5yo
Average Age
Experienced Board: 6VX's board of directors are considered experienced (6.9 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 21:12 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Healios K.K. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hidemaru Yamaguchi | Citigroup Inc |
| Akinori Ueda | Goldman Sachs |
| Miyabi Yamakita | Jefferies LLC |